세계의 알포트 증후군 치료 시장 - 산업규모, 점유율, 동향, 기회, 예측, 제품 유형별, 질환 유형별, 최종 사용자별, 지역별, 경쟁별 (2020-2030년)

Alport Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Disease Type, By End User, By Region, and Competition, 2020-2030F

US $ 4,500 ￦ 6,385,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,805,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,352,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 알포트 증후군 치료 시장은 2024년 968만 달러로 평가되었고, 2030년까지는 1,248만 달러에 이를 것으로 예측됩니다. 예측 기간 동안 CAGR은 4.33%를 나타낼 전망입니다.

알포트 증후군은 주로 신장, 귀, 눈에 영향을 미치는 드문 유전 질환입니다. 신장 기능의 진행성 악화, 청력 상실, 특정 눈의 이상이 특징입니다. 알포트 증후군은 신장, 내이, 눈을 비롯한 다양한 조직의 기저막의 중요한 구성요소인 IV형 콜라겐의 생산 및 구조에 영향을 미치는 유전자 변이에 의해 유발됩니다. 진단에는 일반적으로 임상 평가, 가족력 평가, 혈뇨 및 단백질 소변을 검출하기 위한 소변 검사, 청력 평가, 특정 돌연변이를 확인하기 위한 유전자 검사가 결합됩니다. 현재, 알포트 증후군의 치료법은 없습니다. 치료는 증상의 관리와 질병의 진행을 지연시키는 데 중점을 둡니다. 여기에는 혈압 조절, 단백질 소변을 감소시키는 약물 요법, 보청기 및 인공 내이와 같은 난청에 대한 개입이 포함됩니다. 진행된 경우에는 신장 이식이 필요할 수 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	968만 달러
시장 규모 : 2030년	1,248만 달러
CAGR : 2025-2030년	4.33%
급성장 부문	태블릿
최대 시장	북미

유전자 조사의 진보로 알포트 증후군의 원인이 되는 유전자 변이에 대한 이해가 깊어지고 있습니다. 이를 통해 표적 치료와 맞춤형 의료에 대한 접근이 가능해졌습니다. 진단법과 유전자 검사의 개선으로 알포트 증후군의 발병률과 유병률이 증가하고 있습니다. 이 동향은 치료에 대한 수요를 부추기고 있습니다. 현재 진행 중인 임상시험에서 알포트 증후군에 대한 새로운 치료법 및 치료 전략이 평가되고 있습니다. 긍정적인 시험 결과와 새로운 치료 가능성이 시장 성장을 뒷받침하고 있습니다. 제약업계가 희소질환이나 희소질병용 의약품 개발에 힘을 쏟아지게 됨으로써 알포트 증후군의 치료제 후보 파이프라인이 증가하고 있습니다. 유전자 치료 및 RNA 표적 치료와 같은 치료 접근법의 혁신은 알포트 증후군의 유전적 기초의 치료에 유망합니다.

주요 시장 성장 촉진요인

유전자 연구의 진보

주요 시장 과제

복잡한 유전학

주요 시장 동향

희귀 의약품 지정

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 제품 유형별(정제, 캡슐제, 주사제, 기타)
  • 질환 유형별(X연쇄성 알포트 증후군, 상염색체 열성 알포트 증후군, 상염색체 우성 알포트 증후군)
  • 최종 사용자별(병원 약국, 소매 약국, 전문 클리닉)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제7장 유럽의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 알포트 증후군 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Retrophin, Inc.
• Goldfinch Bio, Inc.
• Regulus Therapeutics Inc.
• ChemoCentryx, Inc.
• Reata Pharmaceuticals, Inc.
• Sanofi SA
• Ionis Pharmaceuticals, Inc.
• Omeros Corporation
• Akebia Therapeutics, Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

SHW

영문 목차

영문목차

Global Alport Syndrome Treatment Market was valued at USD 9.68 million in 2024 and is expected to reach USD 12.48 million by 2030 with a CAGR of 4.33% during the forecast period. Alport syndrome is a rare genetic disorder that primarily affects the kidneys, ears, and eyes. It is characterized by the progressive deterioration of kidney function, hearing loss, and certain eye abnormalities. Alport syndrome is caused by genetic mutations that affect the production and structure of type IV collagen, a crucial component of the basement membranes in various tissues, including the kidneys, inner ear, and eyes. Diagnosis typically involves a combination of clinical evaluation, family history assessment, urine tests to detect hematuria and proteinuria, hearing assessments, and genetic testing to identify specific mutations. There is currently no cure for Alport syndrome. Treatment focuses on managing symptoms and slowing disease progression. This may include blood pressure control, medications to reduce proteinuria, and interventions to address hearing loss, such as hearing aids or cochlear implants. In advanced cases, kidney transplantation may be necessary.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 9.68 Million
Market Size 2030	USD 12.48 Million
CAGR 2025-2030	4.33%
Fastest Growing Segment	Tablet
Largest Market	North America

Advances in genetic research have deepened our understanding of the genetic mutations responsible for Alport syndrome. This has paved the way for targeted therapies and personalized medicine approaches. The incidence and prevalence of Alport syndrome are increasing due to improved diagnostic methods and genetic testing. This trend fuels the demand for treatments. Ongoing clinical trials are evaluating new therapies and treatment strategies for Alport syndrome. Positive trial results and the potential for novel treatments encourage market growth. The pharmaceutical industry's increasing focus on rare diseases and orphan drug development has led to a growing pipeline of potential Alport syndrome treatments. Innovations in therapeutic approaches, such as gene therapy and RNA-targeted therapies, hold promise for treating the genetic basis of Alport syndrome.

Key Market Drivers

Advancements in Genetic Research

Genetic research has led to the identification of the specific genetic mutations responsible for Alport syndrome. This includes mutations in genes like COL4A3, COL4A4, and COL4A5. Understanding these mutations is crucial for diagnosis and targeted therapies. Genetic research has paved the way for personalized medicine approaches. By analyzing a patient's genetic profile, healthcare providers can tailor treatment plans to address the specific genetic subtype of Alport syndrome, increasing treatment effectiveness. Researchers are actively developing targeted therapies that aim to address the underlying genetic defects in Alport syndrome. These therapies, such as gene therapy and RNA-targeted therapies, have the potential to modify or correct the genetic mutations responsible for the disease. Genetic research allows for the assessment of genetic risk within families. This information is valuable for identifying individuals at risk of developing Alport syndrome and for implementing early intervention strategies. Genetic testing can identify carriers of Alport syndrome who may not exhibit symptoms but can pass the condition to their offspring. This information is essential for family planning and genetic counseling. Genetic research has enabled the development of prenatal testing methods to identify Alport syndrome in unborn babies. This allows parents to make informed decisions about pregnancy and potential treatment options.

Key Market Challenges

Complex Genetics

Alport syndrome is genetically heterogeneous, meaning that it can result from various mutations in different genes (COL4A3, COL4A4, and COL4A5). Each of these mutations can have different clinical presentations, making it challenging to develop a one-size-fits-all treatment. The genetic mutations responsible for Alport syndrome can lead to varying disease severity and progression. Some individuals may experience mild symptoms, while others face more severe kidney and hearing problems. Tailoring treatments to the specific genetic subtype and disease stage is complex. Understanding the relationship between specific genetic mutations (genotype) and the resulting clinical symptoms (phenotype) is a complex task. This correlation is not always straightforward, making it challenging to predict disease outcomes and treatment responses.

Some individuals with Alport syndrome-related genetic mutations may not develop noticeable symptoms, a phenomenon known as incomplete penetrance. Determining who will develop clinical symptoms and require treatment is challenging. New genetic mutations associated with Alport syndrome continue to be identified through genetic research. Incorporating these newly discovered mutations into treatment strategies and understanding their clinical significance can be complex. Genetic interactions between multiple genes may influence the disease's presentation and progression. Understanding these multigenic interactions and their implications for treatment is challenging. Even within individuals with the same genetic mutation, there can be significant variability in the presentation and progression of Alport syndrome. This variability complicates the development of standardized treatment approaches. While personalized medicine holds promise for tailoring treatments to an individual's specific genetic profile, implementing personalized treatment strategies requires sophisticated genetic testing, interpretation, and access to targeted therapies.

Key Market Trends

Orphan Drug Designation

Orphan drug designation provides pharmaceutical companies with incentives, such as extended market exclusivity, tax credits, and reduced regulatory fees. These incentives encourage companies to invest in research and development for rare diseases like Alport syndrome. The designation focuses research efforts on rare diseases, including Alport syndrome. Pharmaceutical companies are more likely to allocate resources and conduct clinical trials for orphan-designated drugs.

Orphan drug designation can lead to the development of new treatment options specifically tailored to Alport syndrome. This benefits patients by expanding their choices for managing the condition. Orphan drugs often receive expedited regulatory review processes, which can accelerate the approval and availability of treatments for Alport syndrome. Orphan drug designation can attract more companies to enter the Alport syndrome treatment market, fostering competition and potentially leading to a broader range of therapies. The recognition of orphan drug status can stimulate international collaboration in research and development efforts to address Alport syndrome, leveraging expertise from various regions. Patient advocacy groups and organizations dedicated to rare diseases often actively support orphan drug designation for treatments related to Alport syndrome. Their advocacy can contribute to the development of targeted therapies. Orphan drug designation aligns with the trend toward precision medicine. Designated drugs can be developed to target specific genetic subtypes of Alport syndrome, improving treatment effectiveness.

Key Market Players

• Retrophin, Inc.
• Goldfinch Bio, Inc.
• Regulus Therapeutics Inc.
• Vertex Pharmaceuticals Incorporated
• ChemoCentryx, Inc.
• Reata Pharmaceuticals, Inc.
• Sanofi S.A.
• Ionis Pharmaceuticals, Inc.
• Omeros Corporation
• Akebia Therapeutics, Inc.

Report Scope:

In this report, the Global Alport Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alport Syndrome Treatment Market, By Product Type:

• Tablets
• Capsules
• Injectables
• Others

Alport Syndrome Treatment Market, By Disease Type:

• X-linked Alport Syndrome
• Autosomal Recessive Alport Syndrome
• Autosomal Dominant Alport Syndrome

Alport Syndrome Treatment Market, By End User:

• Hospital Pharmacy
• Retail Pharmacy
• Specialty Clinics

Global Alport Syndrome Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alport Syndrome Treatment Market.

Available Customizations:

Global Alport Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alport Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Tablets, Capsules, Injectable, Others)
  • 5.2.2. By Disease Type (X-linked Alport Syndrome, Autosomal Recessive Alport Syndrome, Autosomal Dominant Alport Syndrome)
  • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Specialty Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Alport Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alport Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Alport Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Alport Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End User

7. Europe Alport Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Alport Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Alport Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Alport Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Alport Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Alport Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Alport Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Alport Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Alport Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Alport Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Alport Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Alport Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End User

9. South America Alport Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Alport Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Alport Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Alport Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Alport Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Disease Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Alport Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Alport Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Alport Syndrome Treatment market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Retrophin, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.6. SWOT Analysis
• 15.2. Goldfinch Bio, Inc.
• 15.3. Regulus Therapeutics Inc.
• 15.5. ChemoCentryx, Inc.
• 15.6. Reata Pharmaceuticals, Inc.
• 15.7. Sanofi S.A.
• 15.8. Ionis Pharmaceuticals, Inc.
• 15.9. Omeros Corporation
• 15.10.Akebia Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료